Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    August 2019
  1. HIGASHIYAMA M, Sugita A, Koganei K, Wanatabe K, et al
    Correction to: Management of elderly ulcerative colitis in Japan.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01606.
    PubMed     Text format     Abstract available


    July 2019
  2. MURAKAMI Y, Nishiwaki Y, Oba MS, Asakura K, et al
    Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey.
    J Gastroenterol. 2019 Jul 15. pii: 10.1007/s00535-019-01603.
    PubMed     Text format     Abstract available


    May 2019
  3. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    PubMed     Text format     Abstract available


  4. PARK S, Chun J, Han KD, Soh H, et al
    Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study.
    J Gastroenterol. 2019 May 15. pii: 10.1007/s00535-019-01589.
    PubMed     Text format     Abstract available


    April 2019
  5. WANG T, Chen N, Ren W, Liu F, et al
    Integrated analysis of circRNAs and mRNAs expression profile revealed the involvement of hsa_circ_0007919 in the pathogenesis of ulcerative colitis.
    J Gastroenterol. 2019 Apr 29. pii: 10.1007/s00535-019-01585.
    PubMed     Text format     Abstract available


  6. HIGASHIYAMA M, Sugita A, Koganei K, Wanatabe K, et al
    Management of elderly ulcerative colitis in Japan.
    J Gastroenterol. 2019 Apr 20. pii: 10.1007/s00535-019-01580.
    PubMed     Text format     Abstract available


    January 2019
  7. NISHIMURA R, Shirasaki T, Tsuchiya K, Miyake Y, et al
    Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01540.
    PubMed     Text format     Abstract available


    December 2018
  8. KINOSHITA K, Katsurada T, Nishida M, Omotehara S, et al
    Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study.
    J Gastroenterol. 2018 Dec 5. pii: 10.1007/s00535-018-01534.
    PubMed     Text format     Abstract available


    November 2018
  9. IMAI T, Inoue R, Kawada Y, Morita Y, et al
    Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2018 Nov 26. pii: 10.1007/s00535-018-1530.
    PubMed     Text format     Abstract available


    August 2018
  10. VAN DER SLOOT KWJ, Weersma RK, Dijkstra G, Alizadeh BZ, et al
    Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ).
    J Gastroenterol. 2018 Aug 14. pii: 10.1007/s00535-018-1501.
    PubMed     Text format     Abstract available


    June 2018
  11. KAKUTA Y, Kawai Y, Okamoto D, Takagawa T, et al
    NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2018 Jun 19. pii: 10.1007/s00535-018-1486.
    PubMed     Text format     Abstract available


  12. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
    J Gastroenterol. 2018 Jun 4. pii: 10.1007/s00535-018-1480.
    PubMed     Text format     Abstract available


  13. NAGANUMA M
    Author's reply: can budesonide form be alterative treatment for ulcerative proctosigmoiditis?
    J Gastroenterol. 2018;53:801-802.
    PubMed     Text format    


    April 2018
  14. POKROTNIEKS J, Sitkin S
    A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.
    J Gastroenterol. 2018 Apr 3. pii: 10.1007/s00535-018-1458.
    PubMed     Text format    


    February 2018
  15. MATSUOKA K, Kobayashi T, Ueno F, Matsui T, et al
    Evidence-based clinical practice guidelines for inflammatory bowel disease.
    J Gastroenterol. 2018 Feb 10. pii: 10.1007/s00535-018-1439.
    PubMed     Text format     Abstract available


    November 2017
  16. KAKUTA Y, Kinouchi Y, Shimosegawa T
    Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
    J Gastroenterol. 2017 Nov 30. pii: 10.1007/s00535-017-1416.
    PubMed     Text format     Abstract available


    October 2017
  17. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1399.
    PubMed     Text format     Abstract available


    September 2017
  18. HANAOKA M, Ishikawa T, Ishiguro M, Tokura M, et al
    Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1387.
    PubMed     Text format     Abstract available


  19. UCHINO M, Ikeuchi H, Sugita A, Futami K, et al
    Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study.
    J Gastroenterol. 2017 Sep 7. doi: 10.1007/s00535-017-1389.
    PubMed     Text format     Abstract available


    August 2017
  20. NISHINO K, Nishida A, Inoue R, Kawada Y, et al
    Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease.
    J Gastroenterol. 2017 Aug 29. doi: 10.1007/s00535-017-1384.
    PubMed     Text format     Abstract available


  21. NAGANUMA M, Aoyama N, Tada T, Kobayashi K, et al
    Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
    J Gastroenterol. 2017 Aug 4. doi: 10.1007/s00535-017-1376.
    PubMed     Text format     Abstract available


    June 2017
  22. KOBAYASHI T, Matsuoka K, Yokoyama Y, Nakamura T, et al
    A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.
    J Gastroenterol. 2017 Jun 8. doi: 10.1007/s00535-017-1356.
    PubMed     Text format     Abstract available


    May 2017
  23. IHARA S, Hirata Y, Koike K
    TGF-beta in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.
    J Gastroenterol. 2017 May 22. doi: 10.1007/s00535-017-1350.
    PubMed     Text format     Abstract available


  24. QIU Y, Chen BL, Mao R, Zhang SH, et al
    Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease.
    J Gastroenterol. 2017;52:535-554.
    PubMed     Text format     Abstract available


  25. RIMOLA J, Alvarez-Cofino A, Perez-Jeldres T, Ayuso C, et al
    Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease.
    J Gastroenterol. 2017;52:585-593.
    PubMed     Text format     Abstract available


  26. BUISSON A, Hordonneau C, Goutte M, Bommelaer G, et al
    What score should be used for evaluation of Crohn's disease severity using magnetic resonance imaging?
    J Gastroenterol. 2017;52:652-653.
    PubMed     Text format    


    April 2017
  27. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Apr 12. doi: 10.1007/s00535-017-1340.
    PubMed     Text format    


    March 2017
  28. HIBI T, Imai Y, Senoo A, Ohta K, et al
    Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    J Gastroenterol. 2017 Mar 21. doi: 10.1007/s00535-017-1326.
    PubMed     Text format     Abstract available


  29. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Mar 20. doi: 10.1007/s00535-017-1325.
    PubMed     Text format     Abstract available


    February 2017
  30. ARAKI M, Shinzaki S, Yamada T, Arimitsu S, et al
    Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease.
    J Gastroenterol. 2017 Feb 6. doi: 10.1007/s00535-017-1313.
    PubMed     Text format     Abstract available


    January 2017
  31. SUN M, Wu W, Liu Z, Cong Y, et al
    Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases.
    J Gastroenterol. 2017;52:1-8.
    PubMed     Text format     Abstract available


    December 2016
  32. NAKAZAWA T, Notohara K, Tazuma S, Tanaka A, et al
    The 2016 diagnostic criteria for primary sclerosing cholangitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  33. IBORRA M, Gisbert JP, Bosca-Watts MM, Lopez-Garcia A, et al
    Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed     Text format    


  34. CHAN HC, Ng SC
    Emerging biologics in inflammatory bowel disease.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  35. NISHIDA A, Imaeda H, Ohno M, Inatomi O, et al
    Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  36. IBORRA M, Perez-Gisbert J, Bosca-Watts MM, Lopez-Garcia A, et al
    Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  37. MARTELLI L, Olivera P, Roblin X, Attar A, et al
    Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  38. KEDIA S, Rampal R, Paul J, Ahuja V, et al
    Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India.
    J Gastroenterol. 2016;51:660-71.
    PubMed     Text format     Abstract available


    June 2016
  39. MUSCI JO, Cornish JS, Dabritz J
    Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.
    J Gastroenterol. 2016;51:531-47.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: